A Better Newspaper

## Overview The U.S. Supreme Court issued its decision in *Hikma Pharmaceuticals USA v. Amarin Pharma, Inc.* in June 2026, holding that Amarin failed to "plausibly allege" that Hikma actively induced infringement of its icosapent ethyl product, marketed as Vascepa (IPWatchdog, June 4, 2026). ## Background The case arose in the context of Hatch-Waxman pharmaceutical litigation and the so-called "skinny label" framework, which allows generic drug manufacturers to launch products with labels carving out patented indications. Amarin alleged that Hikma's conduct — including marketing materials and public statements — induced physicians to prescribe the drug for the patented cardiovascular indication despite the carved-out label. ## The Court's Ruling The Supreme Court scolded the U.S. Court of Appeals for the Federal Circuit (CAFC) for its recent approach to induced infringement pleading, holding that Amarin had not met the plausibility standard required under *Twombly/Iqbal* to proceed with its induced infringement claim (IPWatchdog, June 4, 2026). The decision has potentially far-reaching implications beyond the pharmaceutical industry and Hatch-Waxman litigation. ## Legal Significance **For pharmaceutical patent holders:** The ruling raises the bar for pleading induced infringement against generic entrants using skinny labels. Branded manufacturers will need to allege specific, concrete conduct — not merely the existence of a skinny label — to survive a motion to dismiss. **Beyond pharma:** The Court's rebuke of the CAFC's approach to induced infringement pleading standards may affect infringement litigation across technology, software, and medical device sectors, wherever indirect infringement theories are central. **Strategic implications for generic/biosimilar entrants:** Skinny labeling as a launch strategy may become more defensible, provided manufacturers carefully manage their public communications and marketing materials. ## CAFC Implications The Supreme Court's direct criticism of the Federal Circuit's approach signals ongoing tension between the two courts on patent pleading standards. Practitioners should expect the CAFC to recalibrate its induced infringement jurisprudence in subsequent decisions. ## Open Questions - How will district courts apply the heightened pleading standard across non-pharmaceutical patent cases? - Will the ruling accelerate skinny-label generic launches in other therapeutic areas? - Does the decision affect already-filed suits where induced infringement is alleged on thin pleadings? ## Outlook This decision will likely generate significant motion-to-dismiss practice in pending induced infringement cases and reshape how patent counsel drafts complaints in both pharmaceutical and non-pharmaceutical contexts.